Aptus Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $794K | Sell |
1,513
-73
| -5% | -$38.3K | 0.01% | 563 |
|
|
2025
Q1 | $1.01M | Sell |
1,586
-13
| -0.8% | -$8.24K | 0.01% | 504 |
|
|
2024
Q4 | $1.14M | Buy |
1,599
+625
| +64% | +$445K | 0.01% | 470 |
|
|
2024
Q3 | $1.02M | Buy |
974
+32
| +3% | +$33.6K | 0.02% | 404 |
|
|
2024
Q2 | $990K | Buy |
942
+39
| +4% | +$41K | 0.02% | 391 |
|
|
2024
Q1 | $869K | Buy |
903
+124
| +16% | +$119K | 0.02% | 408 |
|
|
2023
Q4 | $684K | Sell |
779
-25
| -3% | -$22K | 0.02% | 330 |
|
|
2023
Q3 | $662K | Buy |
804
+310
| +63% | +$255K | 0.02% | 336 |
|
|
2023
Q2 | $355K | Buy |
494
+40
| +9% | +$28.7K | 0.01% | 360 |
|
|
2023
Q1 | $373K | Buy |
454
+91
| +25% | +$74.8K | 0.01% | 351 |
|
|
2022
Q4 | $262K | Sell |
363
-140
| -28% | -$101K | 0.01% | 425 |
|
|
2022
Q3 | $347K | Sell |
503
-4
| -0.8% | -$2.76K | 0.01% | 365 |
|
|
2022
Q2 | $300K | Sell |
507
-72
| -12% | -$42.6K | 0.01% | 319 |
|
|
2022
Q1 | $404K | Buy |
+579
| New | +$404K | 0.01% | 314 |
|